Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
6.82
-0.05 (-0.73%)
At close: Nov 13, 2026, 4:00 PM EST
6.82
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:15 AM EST
Arvinas Revenue
Arvinas had revenue of $500.00K in the quarter ending September 30, 2026, a decrease of -98.81%. This brings the company's total for the last twelve months to $275.30M, down -11.85% year-over-year. In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. That makes Arvinas the 15,165th largest company in the world by revenue and 2,663rd in the United States.
Revenue (ttm)
$275.30M
Revenue Growth
-11.85%
P/S Ratio
1.62
Revenue / Employee
$1,119,106
Employees
246
Market Cap
446.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Gyre Therapeutics | 110.06M |
| Assembly Biosciences | 67.01M |
| Prothena Corporation | 52.74M |
| CytomX Therapeutics | 14.03M |
| Oculis Holding AG | 1.12M |
| Shattuck Labs | 1.00M |
| Avalo Therapeutics | 59.00K |
ARVN News
- 4 days ago - Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 9 days ago - Arvinas price target lowered to $15 from $16 at BofA - TheFly
- 11 days ago - Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting - GlobeNewsWire
- 12 days ago - Arvinas files $400M mixed securities shelf - TheFly
- 12 days ago - Arvinas price target lowered to $13 from $18 at H.C. Wainwright - TheFly
- 12 days ago - Arvinas Earnings Call Transcript: Q3 2026 - Transcripts
- 12 days ago - Arvinas Earnings release: Q3 2026 - Filings
- 12 days ago - Arvinas Quarterly report: Q3 2026 - Filings